Clinical efficacy and safety of pravastatin treatment in symptomatic patients — the REGRESS trial

[1]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[2]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[3]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[4]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.

[5]  M. Law,et al.  Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.

[6]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[7]  S. Ellis,et al.  Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). , 1993, The American journal of cardiology.

[8]  G. Block,et al.  The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. , 1993, British journal of clinical pharmacology.

[9]  G. Schuler,et al.  Regular Physical Exercise and Low‐Fat Diet: Effects on Progression of Coronary Artery Disease , 1992, Circulation.

[10]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[11]  E. Bixler,et al.  Effects of lovastatin and pravastatin on sleep efficiency and sleep stages , 1991, Clinical pharmacology and therapeutics.

[12]  D. Shapiro,et al.  Long-term safety and efficacy profile of simvastatin. , 1991, The American journal of cardiology.

[13]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.

[14]  H. Pan,et al.  Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects , 1991, Clinical neuropharmacology.

[15]  H. Taylor,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. , 1991, The American journal of cardiology.

[16]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[17]  A. Goldberg,et al.  Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. , 1990, Atherosclerosis.

[18]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[19]  A. Dobs,et al.  Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. , 1990, Atherosclerosis.

[20]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.

[21]  T. Gross,et al.  Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. , 1990, Archives of internal medicine.

[22]  H. Taylor,et al.  The human lens after 48 weeks of treatment with lovastatin. , 1990, The New England journal of medicine.

[23]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[24]  B Buis,et al.  Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. , 1985, The New England journal of medicine.

[25]  M. Fisher,et al.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[26]  P. Toutouzas,et al.  A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group. , 1993, The American journal of cardiology.

[27]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.

[28]  P. Allhoff,et al.  The Leiden Intervention Trial , 1991 .